Literature DB >> 29955955

[Lupus nephritis].

S Melderis1, T Wiech2, C Iking-Konert1,3, O M Steinmetz4.   

Abstract

Lupus nephritis (LN) is a common major organ manifestation of systemic lupus erythematosus (SLE) and causes significantly increased morbidity and mortality. Thus, all patients with SLE should be regularly screened for LN. While new onset glomerular hematuria or proteinuria are suggestive for LN, a kidney biopsy is the gold standard for diagnosis and classification. The treatment of LN comprises strict blood pressure control and administration of hydroxychloroquine. Aggressive forms of LN require additional treatment with immunosuppressive induction therapy followed by a maintenance phase for several years. Given the high rate of disease recurrence, life-long follow-up control in specialized centers is necessary. Despite optimal care a significant proportion of patients still develop chronic kidney failure. Better disease activity markers as well as more potent and specific therapeutic agents are thus urgently needed.

Entities:  

Keywords:  Autoimmune disease; Connective tissue disease; Glomerulonephritis; Nephrology; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 29955955     DOI: 10.1007/s00393-018-0496-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  48 in total

Review 1.  Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review.

Authors:  A S Levey; L A Inker
Journal:  Clin Pharmacol Ther       Date:  2017-06-05       Impact factor: 6.875

Review 2.  Ten common mistakes in the management of lupus nephritis.

Authors:  Bhadran Bose; Earl D Silverman; Joanne M Bargman
Journal:  Am J Kidney Dis       Date:  2013-12-12       Impact factor: 8.860

Review 3.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  Andrew Smyth; Guilherme H M Oliveira; Brian D Lahr; Kent R Bailey; Suzanne M Norby; Vesna D Garovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

4.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

5.  Does pregnancy have any impact on long term damage accrual and on the outcome of lupus nephritis?

Authors:  Davide Gianfreda; Silvana Quaglini; Giulia Frontini; Francesca Raffiotta; Piergiorgio Messa; Gabriella Moroni
Journal:  J Autoimmun       Date:  2017-06-21       Impact factor: 7.094

Review 6.  A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis.

Authors:  Hans-Joachim Anders; Brad Rovin
Journal:  Kidney Int       Date:  2016-07-01       Impact factor: 10.612

7.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Authors:  F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

8.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

9.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Authors:  Mónica Vigna-Perez; Berenice Hernández-Castro; Octavio Paredes-Saharopulos; Diana Portales-Pérez; Lourdes Baranda; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  Arthritis Res Ther       Date:  2006-05-05       Impact factor: 5.156

10.  Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine.

Authors:  Hans-Joachim Anders; Marc Weidenbusch; Brad Rovin
Journal:  Clin Kidney J       Date:  2015-08-27
View more
  1 in total

1.  Association of GTF2I gene polymorphisms with renal involvement of systemic lupus erythematosus in a Chinese population.

Authors:  Yanming Meng; Yao He; Junlong Zhang; Qibing Xie; Min Yang; Yuning Chen; Yongkang Wu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.